Cynata Therapeutics Ltd Total Assets
Cynata Therapeutics Ltd total assets. Based on the latest financial reports, Cynata Therapeutics Ltd (CYP) holds total assets worth AU$7.20 Million AUD (≈ $5.09 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Cynata Therapeutics Ltd (CYP) total market value for the company's overall valuation and market capitalisation.
Total Assets of Cynata Therapeutics Ltd (2007–2025)
Total assets of Cynata Therapeutics Ltd from 2007 to 2025. This chart illustrates how Cynata Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See CYP share price today for real-time trading data and today's change.
Cynata Therapeutics Ltd - Asset Composition Analysis
Cynata Therapeutics Ltd Total Assets Breakdown (June 2025)
Cynata Therapeutics Ltd total assets breakdown as of June 2025. Cynata Therapeutics Ltd's total assets of AU$7.20 Million consist of 74.3% current assets and 25.7% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 70.2% |
| Accounts Receivable | AU$104.65K | 1.5% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$1.85 Million | 25.7% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Cynata Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Cynata Therapeutics Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cynata Therapeutics Ltd's current assets represent 74.3% of total assets in 2025, a decrease from 98.1% in 2007.
- Cash Position: Cash and equivalents constituted 70.2% of total assets in 2025, down from 91.3% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 1.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 25.7% of total assets.
Cynata Therapeutics Ltd Competitors by Total Assets
Key competitors of Cynata Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Cynata Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.40 | 5.58 | 20.08 |
| Quick Ratio | 4.40 | 5.58 | 20.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$4.13 Million | AU$5.37 Million | AU$13.16 Million |
Cynata Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Cynata Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.12 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -14.2% |
| Total Assets | AU$7.20 Million |
| Market Capitalization | $2.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cynata Therapeutics Ltd's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cynata Therapeutics Ltd's assets decreased by 14.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cynata Therapeutics Ltd (2007–2025)
The table below shows the annual total assets of Cynata Therapeutics Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$7.20 Million ≈ $5.09 Million |
-14.19% |
| 2024-06-30 | AU$8.39 Million ≈ $5.94 Million |
-55.84% |
| 2023-06-30 | AU$18.99 Million ≈ $13.44 Million |
-28.46% |
| 2022-06-30 | AU$26.55 Million ≈ $18.78 Million |
-11.43% |
| 2021-06-30 | AU$29.97 Million ≈ $21.21 Million |
+71.47% |
| 2020-06-30 | AU$17.48 Million ≈ $12.37 Million |
+42.70% |
| 2019-06-30 | AU$12.25 Million ≈ $8.67 Million |
-24.07% |
| 2018-06-30 | AU$16.13 Million ≈ $11.42 Million |
+13.18% |
| 2017-06-30 | AU$14.25 Million ≈ $10.09 Million |
+57.84% |
| 2016-06-30 | AU$9.03 Million ≈ $6.39 Million |
-1.04% |
| 2015-06-30 | AU$9.13 Million ≈ $6.46 Million |
-8.07% |
| 2014-06-30 | AU$9.93 Million ≈ $7.02 Million |
+453.73% |
| 2013-06-30 | AU$1.79 Million ≈ $1.27 Million |
+76.29% |
| 2012-06-30 | AU$1.02 Million ≈ $719.48K |
-16.51% |
| 2011-06-30 | AU$1.22 Million ≈ $861.71K |
-2.48% |
| 2010-06-30 | AU$1.25 Million ≈ $883.62K |
-12.07% |
| 2009-06-30 | AU$1.42 Million ≈ $1.00 Million |
-38.98% |
| 2008-06-30 | AU$2.33 Million ≈ $1.65 Million |
-34.56% |
| 2007-06-30 | AU$3.56 Million ≈ $2.52 Million |
-- |
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more